The safety of sodium glucose transporter 2 inhibitors and trends in clinical and hemodynamic parameters in patients with left ventricular assist devices

Alexander Fardman*, Afek Kodesh, Allison Joyce Siegel, Amitai Segev, Ehud Regev, Elad Maor, Anat Berkovitch, Rafael Kuperstein, Avi Morgan, Eyal Nahum, Yael Peled, Avishay Grupper

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The safety and impact of sodium glucose transporter 2 inhibitors (SGLT2-I) in patients with left ventricular assist devices (LVAD) are unknown. Methods: A retrospective analysis of all consecutive patients who underwent LVAD Heart Mate 3 (HM3) implantation at a single medical center and received SGLT2-I therapy following surgery was conducted. LVAD parameters, medical therapy, laboratory tests, echocardiography, and right heart catheterization (RHC) study results were recorded and compared before and after initiation of SGLT2-I. Results: SGLT2-I medications were initiated in 29 (21%) of 138 patients following HM3 implantation (23 (79%) received Empagliflozin and 6 (21%) Dapagliflozin). The mean age at the time of LVAD implantation was 62 ± 6.7 years, 25 (86%) were male, and 23 (79%) had diabetes mellitus. The median time from HM3 implantation to SGLT2-I initiation was 108 days, IQR (26–477). Following SGLT2-I therapy, the daily dose of furosemide decreased from 47 to 23.5 mg/day (mean difference = 23.5 mg/d, 95% CI 8.2–38.7, p = 0.004) and significant weight reduction was observed (mean difference 2.5 kg, 95% CI 0.7–4.3, p = 0.008). Moreover, a significant 5.6 mm Hg reduction in systolic pulmonary artery pressure (sPAP) was measured during RHC (95% CI 0.23–11, p = 0.042) in a subgroup of 11 (38%) patients. LVAD parameters were similar before and after SGLT2-I initiation (p > 0.2 for all). No adverse events were recorded during median follow-up of 354 days, IQR (206–786). Conclusion: SGLT2-I treatment is safe in LVAD patients and might contribute to reduction in patients sPAP.

Original languageEnglish
JournalArtificial Organs
DOIs
StateAccepted/In press - 2024

Keywords

  • LVAD
  • SGLT2-I
  • diuretics
  • pulmonary artery pressure
  • safety

Fingerprint

Dive into the research topics of 'The safety of sodium glucose transporter 2 inhibitors and trends in clinical and hemodynamic parameters in patients with left ventricular assist devices'. Together they form a unique fingerprint.

Cite this